Heart Failure Management and Pathophysiology

Pathophysiology and Clinical Presentation

The heart cannot pump blood effectively forward in systolic heart failure, leading to decreased cardiac output and compensatory neurohormonal activation, according to the American College of Cardiology 1
Impaired ventricular filling is the core problem in diastolic heart failure, caused by diminished relaxation during early diastole or reduced compliance during early-to-late diastole, as stated by the American College of Cardiology 2
The stiff ventricle elevates filling pressures, causing pulmonary congestion despite preserved systolic function in diastolic heart failure, as noted by the American College of Cardiology 2
Stroke volume and cardiac output remain normal at rest due to elevated filling pressures in diastolic heart failure, but become compromised during exercise, according to the American College of Cardiology 2

Management Approach

The American College of Cardiology recommends ACE inhibitors as the cornerstone of therapy for all symptomatic patients with systolic heart failure and those with significantly reduced left ventricular function, even if asymptomatic 1
ACE inhibitors reduce mortality and should be initiated unless contraindicated in systolic heart failure, as stated by the American College of Cardiology 1
Diuretics manage volume overload in systolic heart failure, according to the American College of Cardiology 1
Positive inotropic agents may be beneficial given the impaired contractility in systolic heart failure, as noted by the American College of Cardiology 1
The goal of diastolic heart failure treatment is to reduce elevated filling pressures without significantly reducing cardiac output, requiring judicious medication dosing to avoid hypotension, as stated by the American College of Cardiology 1
Diuretics and nitrates reduce elevated filling pressures in diastolic heart failure, but must be started at small doses with careful monitoring to prevent hypotension, according to the American College of Cardiology 1
Beta-blockers or calcium channel blockers improve diastolic filling by reducing heart rate, allowing more time for ventricular filling in diastolic heart failure, as noted by the American College of Cardiology 1
Positive inotropic agents are not useful in diastolic heart failure since systolic function is normal or near-normal, as stated by the American College of Cardiology 1
Rate control is essential if atrial fibrillation develops in diastolic heart failure, using agents that suppress AV conduction, according to the American College of Cardiology 1

Diagnostic Distinction

Echocardiography or radionuclide imaging is mandatory to distinguish between systolic and diastolic heart failure, as clinical presentation is identical, as noted by the American College of Cardiology 2
Both conditions activate similar neurohormonal systems, though the stimuli producing these two different phenotypes remain largely unknown, according to the American College of Cardiology 3

Systolic vs. Diastolic Heart Failure: Key Distinctions

Primary Distinguishing Features

The European Society of Cardiology notes that systolic heart failure is characterized by a left ventricular ejection fraction (LVEF) <40%, with dilated left ventricle and large end-diastolic volumes 4, 5
The American Heart Association states that diastolic heart failure is characterized by a LVEF >40-50% (preserved), with normal or only slightly enlarged ventricle 4, 5, 6

Clinical Presentation and Epidemiology

The European Society of Cardiology reports that both systolic and diastolic heart failure present with identical symptoms and signs of heart failure, including breathlessness, fatigue, and ankle swelling 4, 5
The American College of Cardiology notes that diastolic heart failure is primarily a disease of elderly women with hypertension, representing 20-60% of all heart failure patients 7, 8

Prognosis and Treatment Approach

The American Heart Association states that diastolic heart failure carries lower mortality (approximately 8% annually) compared to systolic heart failure (19% annually), but morbidity remains substantial 8
The American College of Cardiology recommends ACE inhibitors as first-line therapy for systolic heart failure, and control of systolic and diastolic hypertension is paramount for diastolic heart failure 9, 7, 6
The European Society of Cardiology notes that beta-blockers can reduce mortality and sudden death in systolic heart failure, and may also be used to reduce heart rate and increase diastolic filling period in diastolic heart failure 7, 6

Diagnostic Criteria

The American College of Cardiology states that diagnosis of diastolic heart failure requires three conditions: (1) symptoms/signs of heart failure, (2) preserved LVEF >40-50%, and (3) no significant valvular abnormalities on echocardiography 7, 8, 6

Starling's Curve and Its Clinical Applications

Core Physiological Principles

The American College of Cardiology recommends understanding the relationship between ventricular preload and stroke volume, as described by Starling's curve, which demonstrates that increased ventricular filling leads to increased contractile force and cardiac output up to an optimal point, beyond which further filling provides no additional benefit, in patients with heart failure 10

Clinical Significance in Heart Failure Management

The European Society of Cardiology notes that in systolic heart failure, the entire Frank-Starling curve shifts downward and rightward, meaning higher filling pressures are required to generate the same stroke volume as a normal heart, and goal-directed fluid therapy can be used to optimize patients on their individual curve, monitoring stroke volume changes with minimally invasive cardiac output monitors 10
The American Heart Association recommends that in patients with severe left ventricular systolic dysfunction (LVEF <30%), higher filling pressures are needed to maintain output, and lower systolic blood pressure has a linear association with worse mortality 11

Practical Bedside Application

The Society of Critical Care Medicine suggests that most patients require crystalloids at 1-4 ml/kg/h to maintain homeostasis, and goal-directed boluses are reserved for high-risk patients or those with large intravascular losses, with a near-zero fluid balance approach preferred to avoid fluid excess leading to perioperative weight gain >2.5 kg 10
The American College of Emergency Physicians recommends considering inotropes when cardiac index <2.5 L/min with reduced contractility, as these patients have exhausted their Frank-Starling reserve, and treating hypotension with vasopressors rather than additional volume when stroke volume fails to increase significantly (>10%) with fluid boluses 10

Critical Clinical Pitfalls

Reducing intra-abdominal pressure below 10-12 mmHg during laparoscopy reduces aortic afterload and improves renal blood flow by optimizing the pressure-volume relationship, according to the World Society of Emergency Surgery 10

Modern Classification and Diagnostic Approach to Heart Failure by Ejection Fraction

Terminology

The terms “preserved ejection fraction” (HFpEF) and “reduced ejection fraction” (HFrEF) are not equivalent to the historic labels “diastolic” and “systolic” heart failure; the older terminology should be abandoned. European Society of Cardiology recommendation. 12
Most patients with heart failure exhibit both systolic and diastolic dysfunction at rest or during exercise, making a strict systolic/diastolic dichotomy artificial. European Society of Cardiology observation. 12
An ejection fraction < 40 % primarily reflects a dilated left‑ventricular cavity with large end‑diastolic volume, rather than a pure measure of contractility. European Society of Cardiology insight. 12

Classification by Ejection Fraction

HFrEF (Heart Failure with Reduced EF) – left‑ventricular ejection fraction ≤ 40 %. American Heart Association guideline. 13
HFmrEF (Heart Failure with Mildly Reduced EF) – left‑ventricular ejection fraction 41–49 %. American College of Cardiology guideline. 14
HFpEF (Heart Failure with Preserved EF) – left‑ventricular ejection fraction ≥ 50 %. American Heart Association guideline. 13

Diagnostic Criteria for HFpEF

HFpEF requires LVEF ≥ 50 % plus objective evidence of cardiac dysfunction, such as elevated natriuretic peptides and/or evidence of elevated LV filling pressures (by echocardiography or invasive hemodynamics). European Society of Cardiology and American College of Cardiology criteria. 15, 14, 16
Diagnosis must not rely solely on symptoms and EF ≥ 50 %; objective markers are essential to differentiate HFpEF from non‑cardiac causes of dyspnea. American College of Cardiology recommendation. 14, 16, 17

Epidemiology

HFpEF accounts for approximately 50 % of all heart‑failure cases. American Heart Association and American College of Cardiology data. 13, 14

Therapeutic Implications

HFrEF: Evidence‑based therapies—including ACE inhibitors, beta‑blockers, and SGLT2 inhibitors—have demonstrated mortality benefit. American Heart Association evidence. 13
HFpEF: Therapies that reduce mortality in HFrEF have not shown similar benefit in HFpEF; management focuses on symptom control, comorbidity optimization, and SGLT2 inhibitors. European Society of Cardiology guidance. 15

Clinical Documentation

Outdated labels such as “diastolic heart failure,” “systolic heart failure,” and “congestive heart failure” should be discontinued to avoid oversimplification and potential mis‑treatment. European Society of Cardiology recommendation. 12

Clinical Overlap Between HFrEF and HFpEF

Shared Symptoms

Patients with heart failure—regardless of whether left‑ventricular ejection fraction is reduced (HFrEF) or preserved (HFpEF)—commonly experience exertional or resting dyspnea, fatigue, and ankle swelling as the primary presenting symptoms. 18

Overlap in Cardiac Dysfunction

Both phenotypes exhibit diastolic abnormalities: most individuals with HFrEF have measurable diastolic filling impairment, while many patients classified as HFpEF display subtle reductions in contractile function despite a preserved ejection fraction. 18